JP2022530050A5 - - Google Patents

Info

Publication number
JP2022530050A5
JP2022530050A5 JP2021562990A JP2021562990A JP2022530050A5 JP 2022530050 A5 JP2022530050 A5 JP 2022530050A5 JP 2021562990 A JP2021562990 A JP 2021562990A JP 2021562990 A JP2021562990 A JP 2021562990A JP 2022530050 A5 JP2022530050 A5 JP 2022530050A5
Authority
JP
Japan
Prior art keywords
approximately
antibody
sodium
sulfate
aspartate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021562990A
Other languages
English (en)
Japanese (ja)
Other versions
JP7671697B2 (ja
JP2022530050A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/061340 external-priority patent/WO2020216847A1/en
Publication of JP2022530050A publication Critical patent/JP2022530050A/ja
Publication of JP2022530050A5 publication Critical patent/JP2022530050A5/ja
Priority to JP2025036010A priority Critical patent/JP2025087851A/ja
Application granted granted Critical
Publication of JP7671697B2 publication Critical patent/JP7671697B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021562990A 2019-04-23 2020-04-23 安定な低粘度抗体製剤およびその使用 Active JP7671697B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025036010A JP2025087851A (ja) 2019-04-23 2025-03-07 安定な低粘度抗体製剤およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
US62/837,518 2019-04-23
EP20305145 2020-02-17
EP20305145.3 2020-02-17
PCT/EP2020/061340 WO2020216847A1 (en) 2019-04-23 2020-04-23 Stable, low-viscosity antibody formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025036010A Division JP2025087851A (ja) 2019-04-23 2025-03-07 安定な低粘度抗体製剤およびその使用

Publications (3)

Publication Number Publication Date
JP2022530050A JP2022530050A (ja) 2022-06-27
JP2022530050A5 true JP2022530050A5 (https=) 2023-05-01
JP7671697B2 JP7671697B2 (ja) 2025-05-02

Family

ID=70295163

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021562990A Active JP7671697B2 (ja) 2019-04-23 2020-04-23 安定な低粘度抗体製剤およびその使用
JP2025036010A Pending JP2025087851A (ja) 2019-04-23 2025-03-07 安定な低粘度抗体製剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025036010A Pending JP2025087851A (ja) 2019-04-23 2025-03-07 安定な低粘度抗体製剤およびその使用

Country Status (15)

Country Link
US (1) US20220218607A1 (https=)
EP (1) EP3958896A1 (https=)
JP (2) JP7671697B2 (https=)
KR (1) KR20220004104A (https=)
CN (1) CN114286690A (https=)
AU (1) AU2020262231A1 (https=)
BR (1) BR112021021099A2 (https=)
CA (1) CA3137464A1 (https=)
CO (1) CO2021015561A2 (https=)
IL (1) IL287435A (https=)
MA (1) MA55750A (https=)
MX (1) MX2021012968A (https=)
SG (1) SG11202111740PA (https=)
TW (1) TW202108171A (https=)
WO (1) WO2020216847A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
IL293563A (en) * 2019-12-05 2022-08-01 Sanofi Aventis Us Llc Formulations of anti-cd38 antibodies for subcutaneous administration
JP2024546152A (ja) * 2021-12-16 2024-12-17 上海宝済薬業股▲ふん▼有限公司 免疫グロブリン分解酵素による切断に対抗するＦｃ変異体
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460944A (en) * 1991-10-28 1995-10-24 Boehringer Mannheim Gmbh Storable protein solution
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
WO2009120684A1 (en) * 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
WO2011028811A2 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AR080428A1 (es) * 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
EP3409289B1 (en) * 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
NZ602685A (en) * 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
JP6345123B2 (ja) * 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
DK3199552T3 (da) * 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
US20160058863A1 (en) * 2014-09-03 2016-03-03 Board Of Regents, The University Of Texas System Low viscosity concentrated protein dispersions
WO2018119142A1 (en) * 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
TW201837053A (zh) * 2016-12-22 2018-10-16 法商賽諾菲公司 具有消耗活性的人源化cxcr3抗體及其使用方法

Similar Documents

Publication Publication Date Title
JP2022530050A5 (https=)
US20260091081A1 (en) A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
TWI738632B (zh) 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
CA2664734C (en) Method of drug delivery for bone anabolic protein
US20230115871A1 (en) A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers
JP5458188B2 (ja) 抗ｃｄ４０抗体の高濃度製剤
US20210169896A1 (en) A cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates
IL275274B2 (en) A conjugate of a tubulysin analog with branched linkers
CA2672902A1 (en) Formulations
EP0252290A2 (en) Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
CA2866692A1 (en) Formulations which prevent formation of antibody aggregates
WO2011012637A4 (en) Subcutaneous anti-her2 antibody formulation
JP2002544241A (ja) 生体活性剤の改良された細胞取り込み
JP7671697B2 (ja) 安定な低粘度抗体製剤およびその使用
WO2024239281A1 (en) Targeted treatment of prostate cancers and other tumors by an antibody-drug conjugate
JP2023549776A (ja) 医薬製剤
WO2008119260A1 (en) A medicinal composition of carmustine, preparation method and application
EP3257524A1 (en) Stabilized solution preparation of pharmaceutical glp-1r antibody fusion protein
RU2021133921A (ru) Стабильные маловязкие составы на основе антитела и пути их применения
JP3421330B2 (ja) ビダラビン注射用乾燥製剤
TWI864690B (zh) 用於皮下投予之包含抗-her2抗體的藥學組合物
JP2024536821A5 (https=)
RU2007115064A (ru) Стойкая лекарственная форма из производных фенилаланина
RU2024111069A (ru) Лиофилизированные препараты полипептида enpp1 и их применение
JP2023533498A (ja) Ｇｈｒｈアナログの低用量医薬組成物及びその使用